What Is the Current FDA-Approved Therapy to Treat Pancreatic Insufficiency for Children With Cystic Fibrosis?

American Lung Association. (2010). Cystic fibrosis. Retrieved from http://www.lungusa.org/assets/documents/publications/solddc-chapters/cf.pdf

Borowitz D. Baker R. D. Stallings V. A. (2002). Consensus report on nutrition for pediatric patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition, 35, 246-259.

Cystic Fibrosis Foundation. (2009). Patient registry, 2008 annual data report. Bethesda, MD: Cystic Fibrosis Foundation. Retrieved from http://www.cff.org/research/ClinicalResearch/PatientRegistryReport/

Durie P. R. (2000). Pancreatic aspects of cystic fibrosis and other inherited causes of pancreatic dysfunction. Medical Clinics of North America, 84(3), 13.

McCance K. L. Huether S. E. (2006). Pathophysiology: The biologic basis for disease in adults and children. St. Louis, MO: Elsevier Mosby.

Munck A. Duhamel J. F. Lamireau T. Luyer B. L. Tallec C. L. Bellon G. . (2009). Pancreatic enzyme replacement therapy for young cystic fibrosis patients. Journal of Cystic Fibrosis, 8, 14-18.

Stapleton D. Mews C. Bulsara M. Sherriff J. Sly P. (2002). Pancreatic enzyme replacement therapy: Adherence to guidelines. Nutrition & Dietetics, 59(4), 260-264.

Trapnell B. Strausbaugh S. Woo M. Tong S. Silber S. Mulberg A. Leitz G. (2011). Efficacy and safety of PANCREAZE® for treatment of exocrine pancreatic insufficiency due to cystic fibrosis. Journal of Cystic Fibrosis, 10(5), 350-356.

U.S. Food and Drug Administration. (2010). Updated questions and answers for healthcare professionals and the public: Use an approved pancreatic enzyme product (PEP). Retrieved from http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationfor PatientsandProviders/ucm204745.htm